Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of SHP607 in extremely premature infants
2020-002726-84Phase 2
- Sponsor
- Premacure
- Start
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of mecasermin rinfabate in bronchopulmonary dysplasia (BPD) (2 arms), sponsored by Premacure. Primary endpoint: Incidence of chronic respiratory morbidity indicators through 5 years corrected age.
02
Drugs
mecasermin rinfabate
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on 2020-002726-84.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002726-84.